C CULLINAN ONCOLOGY INC
| Market Cap | $939.31M |
| P/E Ratio | — |
| Forward P/E | -4.83 |
| Dividend Yield | — |
| Beta | -0.16 |
| 52W Range | $5.68 - $16.74 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 38 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Michaelson JenniferChief Scientific Officer | Sale | 8,000 | $15.68 | $125.44K | 05 Mar 2026 | 05 Mar 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 1,780 | $14.14 | $25.17K | 25 Feb 2026 | 26 Feb 2026 |
| Jacquelyn L SumerChief Legal Officer | Sale | 3,601 | $14.47 | $52.11K | 24 Feb 2026 | 25 Feb 2026 |
| Jennifer MichaelsonChief Scientific Officer | Sale | 3,601 | $14.47 | $52.11K | 24 Feb 2026 | 25 Feb 2026 |
| Nadim AhmedPresident and CEO | Sale | 13,515 | $14.47 | $195.56K | 24 Feb 2026 | 25 Feb 2026 |
| Jeffrey Alan JonesChief Medical Officer | Sale | 4,582 | $14.47 | $66.30K | 24 Feb 2026 | 25 Feb 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 3,601 | $14.47 | $52.11K | 24 Feb 2026 | 25 Feb 2026 |
| Jones Jeffrey AlanChief Medical Officer | Sale | 4,582 | $14.47 | $66.30K | 24 Feb 2026 | 25 Feb 2026 |
| SUMER JACQUELYN LChief Legal Officer | Sale | 3,601 | $14.47 | $52.11K | 24 Feb 2026 | 25 Feb 2026 |
| AHMED NADIMPresident and CEO | Sale | 13,515 | $14.47 | $195.56K | 24 Feb 2026 | 25 Feb 2026 |
| Jennifer MichaelsonChief Scientific Officer | Sale | 1,752 | $13.99 | $24.51K | 23 Feb 2026 | 25 Feb 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 1,752 | $13.99 | $24.51K | 23 Feb 2026 | 25 Feb 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 3,742 | $13.62 | $50.97K | 20 Feb 2026 | 23 Feb 2026 |
| Fenton Mary KayChief Financial Officer | Sale | 4,398 | $13.62 | $59.90K | 20 Feb 2026 | 23 Feb 2026 |
| Jones Jeffrey AlanChief Medical Officer | Sale | 4,982 | $13.62 | $67.85K | 20 Feb 2026 | 23 Feb 2026 |
| SUMER JACQUELYN LChief Legal Officer | Sale | 3,742 | $13.62 | $50.97K | 20 Feb 2026 | 23 Feb 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 8,000 | $14.30 | $114.40K | 20 Feb 2026 | 23 Feb 2026 |
| AHMED NADIMPresident and CEO | Sale | 16,381 | $13.62 | $223.11K | 20 Feb 2026 | 23 Feb 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 416 | $12.03 | $5.00K | 12 Feb 2026 | 13 Feb 2026 |
| Michaelson JenniferChief Scientific Officer | Sale | 4,000 | $12.30 | $49.20K | 22 Jan 2026 | 23 Jan 2026 |
| AHMED NADIMPresident and CEO | Sale | 9,922 | $10.01 | $99.32K | 23 Dec 2025 | 29 Dec 2025 |
| Nadim AhmedPresident and CEO | Sale | 9,922 | $10.01 | $99.32K | 23 Dec 2025 | 29 Dec 2025 |
| Michaelson JenniferChief Scientific Officer | Sale | 1,345 | $10.01 | $13.46K | 19 Dec 2025 | 22 Dec 2025 |
| Michaelson JenniferChief Scientific Officer | Sale | 2,898 | $9.67 | $28.02K | 18 Dec 2025 | 19 Dec 2025 |
| SUMER JACQUELYN LChief Legal Officer | Sale | 3,480 | $9.67 | $33.65K | 18 Dec 2025 | 19 Dec 2025 |
| Jones Jeffrey AlanChief Medical Officer | Sale | 4,632 | $9.67 | $44.79K | 18 Dec 2025 | 19 Dec 2025 |
| Michaelson JenniferChief Scientific Officer | Sale | 995 | $11.90 | $11.84K | 15 Dec 2025 | 16 Dec 2025 |
| Michaelson JenniferChief Scientific Officer | Sale | 2,148 | $12.38 | $26.59K | 12 Dec 2025 | 16 Dec 2025 |
| Michaelson JenniferChief Scientific Officer | Sale | 4,000 | $12.30 | $49.20K | 24 Nov 2025 | 25 Nov 2025 |
| Jennifer MichaelsonChief Scientific Officer | Sale | 4,000 | $12.30 | $49.20K | 24 Nov 2025 | 25 Nov 2025 |
| Lynx1 Capital Management LP10% Owner/ 10% Owner | Buy | 165,667 | $8.40 | $1.39M | 28 Oct 2025 | 30 Oct 2025 |
| Lynx1 Capital Management LP10% Owner/ 10% Owner | Buy | 32,217 | $7.84 | $252.57K | 17 Oct 2025 | 21 Oct 2025 |
| Lynx1 Capital Management LP10% Owner/ 10% Owner | Buy | 150,000 | $8.86 | $1.33M | 16 Oct 2025 | 21 Oct 2025 |
| Lynx1 Capital Management LP10% Owner/ 10% Owner | Buy | 51,500 | $7.94 | $409.05K | 15 Oct 2025 | 21 Oct 2025 |
| Lynx1 Capital Management LP10% Owner/ 10% Owner | Buy | 15,032 | $7.59 | $114.05K | 14 Oct 2025 | 21 Oct 2025 |
| Lynx1 Capital Management LP | Buy | 277,298 | $7.36 | $2.04M | 10 Oct 2025 | 10 Oct 2025 |
| Lynx1 Capital Management LP | Buy | 626,043 | $6.70 | $4.19M | 09 Oct 2025 | 10 Oct 2025 |
| Lynx1 Capital Management LP | Buy | 556,300 | $6.46 | $3.59M | 08 Oct 2025 | 10 Oct 2025 |
Frequently Asked Questions
What is CGEM stock price today?
CULLINAN ONCOLOGY INC (CGEM) is currently trading at $15.90. The stock has a 52-week range of $5.68 to $16.74 and a market capitalization of $939.31M.
Is CGEM a good stock to buy in 2026?
CULLINAN ONCOLOGY INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +97.7%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling CGEM stock?
There have been 38 insider transactions for CGEM in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has CGEM stock performed over the past year?
CULLINAN ONCOLOGY INC (CGEM) has returned +97.7% over the past 12 months. The stock traded between $5.68 and $16.74 during this period, and is currently at $15.90.
Which hedge funds own CGEM (CULLINAN ONCOLOGY INC)?
0 tracked hedge funds currently hold CGEM in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is CGEM's market cap and valuation?
CULLINAN ONCOLOGY INC (CGEM) has a market capitalization of $939.31M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is CGEM's revenue and profitability?
CULLINAN ONCOLOGY INC reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of N/A.
What sector is CGEM in and who are its biggest institutional holders?
CULLINAN ONCOLOGY INC (CGEM) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.